Open company graph database — free web & API
Login

ORTHOREBIRTH Inc.

ORTHOREBIRTH株式会社
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
0
§01

Basic information

BASIC
Head office
3-17-43 Chagakazaki Higashi, Tsuzuki-ku, Yokohama City, Kanagawa PrefectureSources
Chief executive
Yasushige NishikawaSources
Capital
211,175,000  (2 100 million)
Employees (non-consolidated)
Employees (consolidated)
Start date
2011-06-01
End date
§02

Websites

1 DOMAINS
§03

Business

2
Research, development, sales, manufacturing, and repair of medical devices and medical consumablesSourcesSales of pharmaceuticals, quasi-drugs, industrial chemicals, and othersSources
§04

Related companies

0 COMPANIES

—

§05

Network

NETWORK
Drag to move · click to open
§06

History

37 EVENTS

Relocated headquarters to Tsuzuki-ku, Yokohama CitySources

Received investment from six venture capital firmsSources

Obtained ISO13485 certification (Medical Device Quality Management System)Sources

Applied for U.S. FDA approvalSources

ReBOSSIS obtained U.S. FDA 510(k) clearanceSources

ReBOSSIS began sales in the United StatesSources

Established Okinawa Research InstituteSources

Outsourced production of ReBOSSIS to Kaigen Pharma Inc.Sources

Signed a domestic sales partnership agreement with KiSCO Inc.Sources

Established ORTHOREBIRTH USA (Georgetown, Texas)Sources

Started adipose stem cell culture research with Ryukyu UniversitySources

New ReBOSSIS obtained U.S. FDA 510(k) clearance for the trauma fieldSources

Signed a business partnership agreement with Harvest Trading Co. for ReBOSSIS sales in TaiwanSources

Signed a business partnership agreement with CBC Co. for ReBOSSIS sales in EuropeSources

New ReBOSSIS obtained U.S. FDA 510(k) clearance for the spinal fieldSources

ReBOSSIS QDS began sales in the United StatesSources

Started joint development with Theradaptive Inc. for the commercialization of BMP (bone morphogenetic protein) productsSources

Launched sales of stem cell extraction and culture sheets for research purposesSources

Headquarters office moved to current locationSources

Started joint development with Dexerials Co., Ltd. on cell culture substratesSources

Signed a sales agency agreement with Kyocera Medical Technologies, USA, a Kyocera Group companySources

ReBOSSIS received sales approval in TaiwanSources

ReBOSSIS received sales approval in IndiaSources

Launched sales of mask filters (Ortholiverse mask filter)Sources

Closed ORTHOREBIRTH USASources

Obtained manufacturing and sales approval for RevoSis-J in the Japanese marketSources

Opened Yokohama Research InstituteSources

Started sales of RevoSis-JSources

Signed a business partnership agreement with Teijin Nakashima Medical Co., Ltd. for domestic salesSources

Signed a sales agency agreement with Matsukaze Co., Ltd. and Teijin Medical Technology Co., Ltd. for domestic oral and plastic surgery salesSources

Signed a basic transaction agreement with Kyocera Corporation for domestic oral and plastic surgery salesSources

Signed a sales agency agreement with Japan Medical Next Co., Ltd. for oral, plastic, and neurosurgery salesSources

Closed Okinawa Research InstituteSources

Established our laboratory at Nagoya Institute of TechnologySources

Launched sales of RevoSis by Surgical Spine Co., Ltd.Sources

Started manufacturing of RevoSis by NISSHA Co., Ltd.Sources

Started sales of CBF, a cotton-shaped artificial bone, by Japan Striker Co., Ltd.Sources

§07

News

15 ARTICLES

Completion of Voluntary Recall of Products for the U.S. MarketSources

We report that the voluntary recall of products for the U.S. market has been completed.

U.S. Product Withdrawal ReportSources

ORTHOREBIRTH has initiated a voluntary recall in the U.S. of its cotton-shaped synthetic bone graft, sold as BioCera Fibers and Zenbone. The recall affects products shipped between May and December 2025 after some raw materials were found to be outside specifications.

Notice of Working from Home Due to Typhoon No. 6 ApproachingSources

Due to the expected approach of Typhoon No. 6, all employees will work from home on June 3, 2026. Operations will continue as usual, but there may be delays or inability to respond to inquiries by phone. Please contact via email or reach out to the relevant personnel for inquiries. Regular operations are scheduled to resume on June 4.

Report on Voluntary Recall of Products for the U.S. MarketSources

Report on Voluntary Recall of Products for the U.S. Market

Completed Funding of 220 Million YenSources

ORTHOREBIRTH Inc. announced on May 12, 2026, that it had successfully raised approximately 220 million yen through a third‑party rights issue with six underwriting companies.

ATEC Japan begins selling cotton-like artificial bone “FlexFIBER”Sources

OrthoRebirth began selling its cotton-like artificial bone “FlexFIBER” in February 2026 through ATEC Japan, with which it signed a distribution agreement in October 2025. The company’s artificial bone has been sold in the United States since February 2015 and in Japan since September 2021, and is used in fields such as orthopedics.

ATEC Japan Starts Selling FlexFIBERSources

ATEC Japan began sales of ORTHOREBIRTH’s cotton-like synthetic bone product, FlexFIBER, in February 2026. The launch follows a distribution agreement between the companies signed in October 2025.

Selling Cotton-Shaped Artificial Bone in Nine Middle Eastern CountriesSources

Orsoliverse Co., Ltd. has signed a contract with Lunatus Marketing & Consulting FZCO of the UAE to sell cotton-shaped artificial bone in Middle Eastern countries. The company will apply for sales approval from the UAE and Saudi Arabia, proceed with procedures in all nine countries over one year, and plan to sell sequentially.

ORTHOREBIRTH Launches Synthetic BoneSources

ORTHOREBIRTH Co., Ltd. has signed an agency agreement with Lunatus Marketing & Consulting FZCO to distribute its cotton‑like synthetic bone product in Middle Eastern countries. The partnership aims to expand the availability of the product across the region.

Revisit “Business Leaders’ Radio”Sources

You can watch our president’s appearance on “Business Leaders’ Radio” on the official ABC Radio YouTube channel. The episode discusses the founding of OrthoReverse, the president’s views on management, and artificial bone. The first part, broadcast on November 2, and the second part, broadcast on November 9, are now available.

§08

Public records

GOV
National Tax Agency basic information5020001091247
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
ORTHOREBIRTH株式会社
Trade name (kana)
オルソリバース
Name in English
Corporation type
301
Address
〒224-0033 神奈川県横浜市都筑区茅ケ崎東3丁目17番43号
Postal code
2240033
Prefecture code
14
City code
118
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-05-24
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
2780987
METI gBizINFO5020001091247
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
5020001091247
Trade name
ORTHOREBIRTH株式会社
Trade name (kana)
オルソリバース
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
神奈川県横浜市都筑区茅ケ崎東3丁目17番43号
Postal code
2240033
Prefecture
神奈川県
Prefecture code
14
City or district
横浜市都筑区
City code
118
Street address
茅ケ崎東3丁目17番43号
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
Capital
Employees
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-05-24
Key information
5020001091247
§09

Sources & updates

SOURCES
↑